Grace Therapeutics (GRCE) Deferred Taxes (2023 - 2026)

Grace Therapeutics has disclosed Deferred Taxes across 4 years of filings, most recently posting -$1.7 million for Q1 2026.

• In Q1 2026, Deferred Taxes fell 66.5% year-over-year to -$1.7 million; the TTM figure through Mar 2026 stood at -$1.7 million (up 46.91% YoY), while the FY2026 annual figure was -$1.7 million, up 46.91% from the prior year.
• Deferred Taxes came in at -$1.7 million for Q1 2026 at Grace Therapeutics, down from -$1.0 million in the prior quarter.
• In the past five years, Deferred Taxes ranged from a high of $2.6 million in Q1 2024 to a low of -$1.7 million in Q1 2026.
• Average Deferred Taxes over 4 years is -$361714.3, with a median of -$724000.0 recorded in 2024.
• Year-over-year, Deferred Taxes plunged 190.87% in 2024 and plunged 66.5% in 2026.
• Over 4 years, Deferred Taxes stood at -$208000.0 in 2023, then sank by 190.87% to -$605000.0 in 2024, then plunged by 68.76% to -$1.0 million in 2025, then slumped by 66.5% to -$1.7 million in 2026.
• Per Business Quant data, the three most recent Deferred Taxes figures were -$1.7 million in Q1 2026, -$1.0 million in Q1 2025, and -$605000.0 in Q4 2024.